SBIR/STTR Research Award
Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis
Award amount
$1,468,122Program and phase
SBIR · Phase IIAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VIA THERAPEUTICS, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YHRZATLXKL46
- Solicitation number
- 75N93023R00005
- Topic code
- 97
Research abstract
To develop and test a low-cost, easy-to-administer drug formulation intended for use in treating rifampicin-resistant pulmonary tuberculosis in pediatric patient populations.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM
- Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization
- Inhalable dry powders of mycobacteriophages for tuberculosis therapy
- Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza
- Development of synergistic clofazimine-amikacin inhalable powders for the treatment of pulmonary Mycobacterium abscessus infections
Research funding history
12 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $9,158,098. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services